Merup M - Search Results

1

Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha.

Merup M, Aberg W, Löfvenberg E, Svensson E, Engman K, Paul C, Gardulf A. Merup M, et al. Acta Oncol. 2002;41(1):50-5. doi: 10.1080/028418602317314064. Acta Oncol. 2002. PMID: 11990518

2

[New recommendations on chronic myeloproliferative diseases. New knowledge must yield new practice].

Merup M, Löfvenberg E, Palmblad J. Merup M, et al. Lakartidningen. 2009 Jan 14-20;106(3):98-9. Lakartidningen. 2009. PMID: 19248458 Swedish. No abstract available.

3

Interferon antibodies in thrombocythemia.

Merup M, Engman K, Paul C. Merup M, et al. J Interferon Res. 1994 Aug;14(4):187-9. doi: 10.1089/jir.1994.14.187. J Interferon Res. 1994. PMID: 7822871 Clinical Trial. No abstract available.

4

Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis.

Törnebohm-Roche E, Merup M, Lockner D, Paul C. Törnebohm-Roche E, et al. Among authors: merup m. Am J Hematol. 1995 Mar;48(3):163-7. doi: 10.1002/ajh.2830480305. Am J Hematol. 1995. PMID: 7864024 Clinical Trial.

5

Human leucocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alfa 2a.

Merup M, Törnebohm-Roche E, Engman K, Paul C. Merup M, et al. Eur J Cancer. 1994;30A(11):1729-30. doi: 10.1016/0959-8049(94)90604-1. Eur J Cancer. 1994. PMID: 7833154 No abstract available.

6

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.

Palmblad J, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Mauritzson N, Westin J, Samuelsson J, Birgegård G. Palmblad J, et al. Among authors: merup m. Int J Med Sci. 2008 Apr 13;5(2):87-91. doi: 10.7150/ijms.5.87. Int J Med Sci. 2008. PMID: 18414650 Free PMC article. Clinical Trial.

7

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Birgegård G, et al. Among authors: merup m. Haematologica. 2004 May;89(5):520-7. Haematologica. 2004. PMID: 15136214 Clinical Trial.

8

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

Nahi H, Lehmann S, Bengtzen S, Jansson M, Möllgård L, Paul C, Merup M. Nahi H, et al. Among authors: merup m. Leuk Lymphoma. 2008 Mar;49(3):508-16. doi: 10.1080/10428190701861645. Leuk Lymphoma. 2008. PMID: 18297528

9

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.

Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Björkholm M, Löfvenberg E, Markevärn B, Merup M, Nilssson L, Palmblad J, Samuelsson J, Birgegård G. Ejerblad E, et al. Among authors: merup m. Hematology. 2013 Jan;18(1):8-13. doi: 10.1179/1607845412Y.0000000023. Epub 2012 Sep 14. Hematology. 2013. PMID: 22990042 Free article. Clinical Trial.

10

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.

Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C. Nahi H, et al. Among authors: merup m. Br J Haematol. 2006 Jan;132(2):230-6. doi: 10.1111/j.1365-2141.2005.05851.x. Br J Haematol. 2006. PMID: 16398657 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters